Population pharmacokinetics terminal half-life estimates
| Patient ID . | Before rondaptivon pegol . | On rondaptivon pegol . | ||||||
|---|---|---|---|---|---|---|---|---|
| INN . | IU . | IU/kg . | Terminal half-life, h (95% CrI) . | IU . | IU/kg . | Terminal half-life, h (95% CrI) . | Fold increase . | |
| 1 | Efmoroctocog alfa | 4000 | 54.1 | 20.6 (19.2-22.1) | 4000 | 54.1 | 56.0 (50.8-61.8) | 2.72 |
| 2 | Lonoctocog alfa | 4000 | 34.8 | 8.3 (7.0-9.9) | 4000 | 36.4 | 33.2 (29.1-38.0) | 3.99 |
| 3 | Lonoctocog alfa | 3000 | 31.9 | 15.5 (13.3-18.2) | 3000 | 31.2 | 28.5 (23.8-34.1) | 1.83 |
| 4 | Moroctocog alfa | 2000 | 25.0 | 9.1 (8.0-10.3) | 2000 | 23.0 | 40.7 (34.6-47.9) | 4.48 |
| 5 | Moroctocog alfa | 1500 | 21.4 | 10.0 (8.4-12.0) | 2000 | 25.0 | 26.8 (23.4-30.7) | 2.67 |
| 6 | Moroctocog alfa | 1000 | 17.2 | 13.1 (11.2-15.3) | 2000 | 33.9 | 31.9 (27.3-37.2) | 2.43 |
| 7 | Octocog alfa | 2000 | 25.6 | 8.6 (7.7-9.6) | 2000 | 24.8 | 20.8 (17.2-25.1) | 2.42 |
| 8 | Octocog alfa | 3000 | 42.3 | 10.7 (8.9-12.9) | 3000 | 42.3 | 30.3 (24.0-38.2) | 2.82 |
| 9 | Octocog alfa | 3900 | 50.2 | 16.4 (14.9-18.1) | 2000 | 24.4 | 22.8 (19.8-26.3) | 1.39 |
| Median fold increase: | 2.67 (IQR, 2.42-2.82) | |||||||
| Patient ID . | Before rondaptivon pegol . | On rondaptivon pegol . | ||||||
|---|---|---|---|---|---|---|---|---|
| INN . | IU . | IU/kg . | Terminal half-life, h (95% CrI) . | IU . | IU/kg . | Terminal half-life, h (95% CrI) . | Fold increase . | |
| 1 | Efmoroctocog alfa | 4000 | 54.1 | 20.6 (19.2-22.1) | 4000 | 54.1 | 56.0 (50.8-61.8) | 2.72 |
| 2 | Lonoctocog alfa | 4000 | 34.8 | 8.3 (7.0-9.9) | 4000 | 36.4 | 33.2 (29.1-38.0) | 3.99 |
| 3 | Lonoctocog alfa | 3000 | 31.9 | 15.5 (13.3-18.2) | 3000 | 31.2 | 28.5 (23.8-34.1) | 1.83 |
| 4 | Moroctocog alfa | 2000 | 25.0 | 9.1 (8.0-10.3) | 2000 | 23.0 | 40.7 (34.6-47.9) | 4.48 |
| 5 | Moroctocog alfa | 1500 | 21.4 | 10.0 (8.4-12.0) | 2000 | 25.0 | 26.8 (23.4-30.7) | 2.67 |
| 6 | Moroctocog alfa | 1000 | 17.2 | 13.1 (11.2-15.3) | 2000 | 33.9 | 31.9 (27.3-37.2) | 2.43 |
| 7 | Octocog alfa | 2000 | 25.6 | 8.6 (7.7-9.6) | 2000 | 24.8 | 20.8 (17.2-25.1) | 2.42 |
| 8 | Octocog alfa | 3000 | 42.3 | 10.7 (8.9-12.9) | 3000 | 42.3 | 30.3 (24.0-38.2) | 2.82 |
| 9 | Octocog alfa | 3900 | 50.2 | 16.4 (14.9-18.1) | 2000 | 24.4 | 22.8 (19.8-26.3) | 1.39 |
| Median fold increase: | 2.67 (IQR, 2.42-2.82) | |||||||
Eight patients with severe hemophilia received 6 doses of rondaptivon pegol plus their usual FVIII replacement therapy. Patient 9 was treated on-demand and received only 3 doses of 3 mg rondaptivon pegol.
CrI, credible interval; INN, international nonproprietary name.